Table 1 Patient characteristics of 6 MMR-proficient CRC patients treated with ICI.
Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---|---|---|---|---|---|---|
Primary tumor site | Rectum | Rectum | Rectum | Rectum | Rectum | Colon |
Stage | T2N0M0 | T3N0M0 | T3N0M0 | T3N1M0 | T4aN1aM0 | T3N0M0 |
Metastatic site | NO | NO | NO | NO | NO | NO |
Treatment before ICI | ||||||
Systematic (response¶) | None | FOLFOX + radiotherapy (PR) | FOLFOX (PR) | None | FOLFOX (PD) | XELOX (PD) |
Surgery | None | None | None | None | Hartmann | Right hemicolectomy |
ICI combined treatment | ||||||
Regimen | Sintilimab + Avastin + FOLFOX | FOLFOX + sintilimab | FOLFOX + sintilimab | sintilimab + FOLFOX | Camrelizumab | Nivolumab |
Systematic (response¶) | PR | PR | PR | PD | PD | PD |
Radiological response | PR | PR | PR | PD | Ξ | Ξ |
Surgical treatment (after ICI) | Dixon | TaTME | Dixon | Dixon | Ξ | Ξ |
Pathological response | ||||||
Primary tumor | PR | PR | PR | PD | Ξ | Ξ |
Reginal lymph nodes | PR | PR | PR | PD | Ξ | Ξ |
Postoperative treatment | None | None | FOLFOX | FOLFOX | Camrelizumab | Nivolumab |
TRG score (NCCN Guidelines) | 1 | 1 | 1 | 2 | Ξ | Ξ |
